Isis' Genetrove launches human gene function database
Isis Pharmaceuticals says that its GeneTrove division has introduced theantisense technology-based Human Gene Function Database, which it claims is the first of its type to contain information on the selective inhibition of 10,000 human genes.
The company added that "the breadth of GeneTrove's information-rich database will enable industry partners to efficiently identify which genes are critical in human disease and represent attractive drug targets." It goes on to say that, by providing "the most comprehensive biological view of the human genome to date," the firm's partners can rapidly prioritize genomic information to identify and discover new targets.
GeneTrove will preview the database during the upcoming IBC Drug Discovery Technology 2001 conference in Boston, USA, which runs August 13-17.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze